Phenotypic Variability and Newly Identified Mutations of the <i>IVD </i>Gene in Japanese Patients with Isovaleric Acidemia
-
- Sakamoto Osamu
- Department of Pediatrics, Tohoku University School of Medicine
-
- Arai-Ichinoi Natsuko
- Department of Pediatrics, Tohoku University School of Medicine
-
- Mitsubuchi Hiroshi
- Department of Neonatology, Kumamoto University Hospital
-
- Chinen Yasutsugu
- Department of Pediatrics, Faculty of Medicine, University of the Ryukyus
-
- Haruna Hidenori
- Department of Pediatrics, Juntendo University Faculty of Medicine
-
- Maruyama Hidehiko
- Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
-
- Sugawara Hidenori
- Yokohama City University Medical Center, Children’s Medical Center
-
- Kure Shigeo
- Department of Pediatrics, Tohoku University School of Medicine
Search this article
Abstract
Isovaleric acidemia (IVA) is an autosomal recessive inborn error affecting leucine metabolism. It is caused by a deficiency in isovaleryl-CoA dehydrogenase (IVD), a mitochondrial matrix enzyme that catalyzes the oxidation of isovaleryl-CoA to 3-methylcrotonyl-CoA. IVD is a FAD-containing enzyme, consisting of four identical subunits. Clinical features of IVA include poor feeding, vomiting, lethargy, developmental delay, metabolic acidosis, and a characteristic “sweaty foot” odor. IVA is one of the target disorders for newborn screening by tandem mass spectrometry (MS/MS). The human IVD gene is located on chromosome 15q. To date, over 50 disease-causing mutations have been reported worldwide. In this study, we searched for IVD mutations in five Japanese patients with IVA (neonatal type, two patients; chronic intermittent type, two patients; and mild biochemical type, one patient). The diagnosis of IVA was confirmed by urinary organic acid analysis using gas chromatography and mass spectrometry. All coding exons and the flanking introns in the IVD gene were amplified by PCR and were directly sequenced. We thus identified six hitherto unknown mutations (p.G94D, p.E116K, p.M167T, p.L243P, p.L246P, and c.696+1G>T) and four previously reported (p.R53P, p.R395C, p.Y403C, and p.E411K) pathogenic mutations. All patients were compound heterozygotes, and each mutation was identified in a single patient. Pathogenicity of newly identified mutations was validated using computational programs. Among them, the p.M167T is believed to influence FAD binding, as the position 167 is present in one of the FAD-binding sites. Our results have illustrated the heterogeneous mutation spectrum and clinical presentation of IVA in the Japanese patients.
Journal
-
- The Tohoku Journal of Experimental Medicine
-
The Tohoku Journal of Experimental Medicine 236 (2), 103-106, 2015
Tohoku University Medical Press